What's Hot
View all perspectives
Dr. John Cush RheumNow
3 years 6 months ago
Q-DAPSA for Measuring Disease Activity in PsA by Dr. Rachel Tate ( @uptoTate) #EULAR2021
https://t.co/fbi3Kbd2GS https://t.co/afRnle1EJK
Dr. Rachel Tate uptoTate
3 years 6 months ago
Abstract #POS0296: real-world bDMARD dosing in axSpA and PsA: TNFi are used in approved dosing for most pts, but, non-TNFi-bDMARDs were often used in higher doses, corresponding to increased PsO dosing. #EULAR2021 @RheumNow https://t.co/7Br5UWtHJo https://t.co/UC4UYQpxml
k dao KDAO2011
3 years 6 months ago
Would you take an SLE patient off of HCQ after 15 years of use seeing this data? @rheumnow @Lupusreference @LupusDocLim @Lupusdoc1 @LupusMD
k dao KDAO2011
3 years 6 months ago
Per Dr. Dorner: women have higher rates of HCQ assc cardiac conduction abnormalities... not sure why... maybe because we prescribe this drug more in women? maybe because they have small volume of distribution than men? maybe women metabolize the medicine differently than men? https://t.co/X9YYJG3Zf0
David Liew drdavidliew
3 years 6 months ago
oh... and this from Ernest Choy and Clive Kelly.
Combination therapy with anti-IL-6/anti-fibrotics for RA-ILD? 👀
OP0124 #EULAR2021 @RheumNow https://t.co/oaGjRgkq0x
David Liew drdavidliew
3 years 6 months ago
Nintedanib stalls *progressive fibrosing* RA-ILD
(including across CRP and steroid subgroups).
Presuming you can tolerate it, maybe there's something we can do for your RA-ILD now, apart from just controlling your arthritis!
subanalysis from INBUILD #EULAR2021 @RheumNow https://t.co/hJCd37oRqK
David Liew drdavidliew
3 years 6 months ago
Clever from @DanielAletaha's group, asking: have trial patients really been MTX-optimised pre-enrollment?
Placebo arm data from bDMARD trials x2:
MTX continuation ACR20 w16: 25% v 12%
(MTX works!)
Should clinical trials have mandatory run-in periods?
OP0127 #EULAR2021 @RheumNow https://t.co/Sx3IKOVKB6
David Liew drdavidliew
3 years 6 months ago
I'm not always a 'What Is New' session kind of guy, but given that it's Maria Cid introducing the always insightful @Sarah_L_Mackie on GCA I'll happily join the other 1012 viewers at #EULAR2021 tuning in!
(So far, definitely and elegantly worth it.) @RheumNow https://t.co/kHOus21T1z
David Liew drdavidliew
3 years 6 months ago
After many years without love, RA-ILD therapy seems like it's on the move.
MUC5B aside, we've seen abstracts at #EULAR2021 about:
- tofacitinib (OP0125)
- abatacept (POS0513)
- rituximab (POS0645)
- nintedanib (below)
I discuss it a bit for @RheumNow:
https://t.co/nk87kfjacb https://t.co/EjNbA2oLWs
David Liew drdavidliew
3 years 6 months ago
Great to have my @OMERACT irAE group co-chair and friend @MarieKostine remind #EULAR2021 of the EULAR points to consider for irAEs - still relevant in a fast-moving field!
available here in full @ARD_BMJ: https://t.co/wFZqKsdDoz
in the Oncorheumatology session @RheumNow https://t.co/RuhIlkFRgM
David Liew drdavidliew
3 years 6 months ago
I remember when we used to teach residents how to differentiate RA & PsA patients on imaging from normal scans.
Give the right computer a whole lot of HR-pQCT scans, and it probably can do as well as the teaching rheumatologist...
@LkasDer @maier_ak OP0145 #EULAR2021 @RheumNow https://t.co/kFx3oKzWKc
David Liew drdavidliew
3 years 6 months ago
All credit to the @karolinskainst @Rigshospitalet @WH_Rheumatology investigators for:
- tackling this issue
- bringing it to #EULAR2021
- acknowledging limitations publicly & graciously
😊
It's... complicated. But each time we get closer!
OP0210 https://t.co/2L3RDH276v @RheumNow https://t.co/UtcTukt3r8
David Liew drdavidliew
3 years 6 months ago
We know dementia (which is a/w inflammation) used to be a problem for RA pts.
What's happened with that as we've got better at treating RA?
Not only has dementia in RA pts decreased over time, the gap with non-RA pts has completely closed!
@KronzerMD OP0216 #EULAR2021 @RheumNow https://t.co/bbbnQtv4vE
David Liew drdavidliew
3 years 6 months ago
The advantage of the #EULAR2021 portal - the motivated speaker can answer all the excellent questions that the chairs don't ask! @RheumNow https://t.co/hewk02lFfM
David Liew drdavidliew
3 years 6 months ago
We keep on advancing in rheumatology but some things stay the same:
Our RA pts are stuck with multimorbidity more than other pts, esp for the women
(➡️depression, hypothyroid, T2DM, lung dx)
How can we support all of our pts needs better?
@MayoClinic OP0213 #EULAR2021 @RheumNow https://t.co/0Y96Xa0fi2
Poster Hall